Executive Summary
Comcast Cable Communications challenges Entropic's patent (US 10135682) via IPR, arguing that the claims are obvious over various combinations of prior art. The challenger relies on numerous grounds combining references like Cooper-Saey and Prodan-Jalali to demonstrate predictability in wireless communications technology.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Comcast Corporation et al. vs Entropic Communications LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Shenzhen Root Technology Co., Ltd. et al.vsChiaro Technology Ltd.
The PTAB issued a Final Written Decision determining that all 46 challenged claims of the '380 patent were unpatentable. The petitioner successfully argued obviousness (103) over various prior art references, including Chang, Fang, and Yuen, concerning breast pump systems.
Avanos Medical, Inc.vsStratus Medical, LLC
Avanos Medical challenges Stratus Medical's RF neurotomy needle claims at the PTAB, asserting obviousness under 35 U.S.C. § 103. The Petitioner argues that combining multiple prior art references—including Racz, Fitz, and Lee—would have motivated a Person of Ordinary Skill in the Art to create the claimed device.
AZURITY PHARMACEUTICALS, INC.vsHelsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR against Helsinn Healthcare's '515 patent covering anti-emetic agents. The Board found a reasonable likelihood of prevailing based on obviousness (103) and prior art, allowing the challenge to proceed.
Revvo Technologies, Inc.vsCerebrum Sensor Technologies, Inc.
The PTAB granted institution of the IPR for Revvo Technologies against Cerebrum Sensor Technologies, allowing claims to be challenged on obviousness grounds after a remand. The Board ruled that Petitioner provided sufficient justification for differing claim construction positions.
Merck Sharp & Dohme LLC et al.vsThe Johns Hopkins University
The PTAB found all 28 challenged claims unpatentable in this IPR proceeding concerning oncology/immunotherapy. The Petitioner successfully demonstrated that the MSI-H Study Record inherently anticipated or rendered obvious the claimed methods under both § 102 and § 103.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.